BioCentury
ARTICLE | Product Development

GreenLight signals mRNA vaccine deal with Serum Institute of India

SII to manufacture and commercialize GreenLight’s planned shingles vaccine; deal could include two other RNA products

March 14, 2022 3:37 PM UTC

GreenLight has signed an agreement with Serum Institute of India that aims to create a low-cost, easily stored mRNA shingles vaccine that could be accessible to billions of people living in developing countries.

The collaboration brings together mRNA manufacturing technology from GreenLight Biosciences Holdings (NASDAQ:GRNA), as well as its aspirations as a public benefit corporation, with the capabilities of the Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume...



Access The Full Article